Moderna is an American biotechnology company that develops vaccines and therapies based on mRNA technology. Recent coverage centers on founder Noubar Afeyan, who discussed how AI is reshaping scientific discovery with executives from Google DeepMind and Biocon at the 2026 Bloomberg New Economy Forum and called for urgent regulation of AI agents. Separately, MIT researchers used AI to adjust lipid nanoparticle formulations, producing RNA vaccines stable at room temperature for up to a year.
Moderna founder urges urgent regulation of AI agentsBillionaire biotech entrepreneur and Moderna founder Noubar Afeyan called for urgent regulation of the AI agents tech firms are selling, warning that waiting for a disaster would repeat the drug industry's past mistakes.
Moderna, DeepMind, Biocon execs discuss AI in scienceAt the 2026 Bloomberg New Economy Forum in New Delhi, Moderna co-founder Noubar Afeyan, Google DeepMind Chief AI Readiness Officer Lila Ibrahim and Biocon founder Kiran Mazumdar-Shaw discussed with Bloomberg's Francine Lacqua how AI is reshaping scientific discovery.
MIT uses AI to create heat-resistant RNA vaccinesMIT researchers used an AI algorithm to tweak lipid nanoparticle formulations, yielding RNA vaccines stable at room temperature for up to a year or at nearly 100°F for two months, with mouse immune responses matching a Moderna-like shot. Published in Nature Biotechnology, the AI predictions cut experiment counts.
UNC receives $40M to use AI for personalized cancer vaccinesUNC-Chapel Hill has received $40 million from the OpenAI foundation nonprofit for a four-year project called "Generative Immunotherapy" to use AI to create personalized cancer vaccines. The first trial will target triple-negative breast cancer patients after surgery, with data from 75 people collected to identify optimal tumor targets.
The A.I. Daily